Rebagit pills 100mg, 30pcs

Composition

of 1 tab. : rebamipid 100 mg. Auxiliary substances: mannitol-35.7 mg, croscarmellose sodium-14 mg, pregelatinized starch-80.7 mg, sodium lauryl sulfate-2 mg, citric acid-2.3 mg, purified talc-3.1 mg, magnesium stearate-2.2 mg. Composition of the film shell: hypromellose – 2.77 mg, purified talc-0.57 mg, titanium dioxide-1.11 mg, propylene glycol-0.55 mg

Pharmacological action

Clinical and pharmacological group: Gastroprotectorpharmacotherapy group: Gastroprotective mediatopharmacological action Cerebamipide increases the content of prostaglandin E2 (PGE2) in the gastric mucosa and increases the content of PGE2 and GI2 in the contents of gastric juice. It has a cytoprotective effect on the gastric mucosa under the damaging effects of ethanol, acids and alkalis, acetylsalicylic acid. Promotes the activation of enzymes that accelerate the biosynthesis of high-molecular glycoproteins, and increases the content of mucus on the surface of the stomach wall. It improves blood supply to the gastric mucosa, activates its barrier function, activates the alkaline secretion of the stomach, increases the proliferation and exchange of gastric epithelial cells, cleanses the mucosa of hydroxyl radicals and suppresses superoxides produced by polymorphonuclear leukocytes and neutrophils in the presence of Helicobacter pylori, protects the gastric mucosa from bacterial damage, has a gastroprotective effect when exposed to the mucosa of NSAIDs. Pharmacokineticsabsorption and distributionafter use at a dose of 100 mg, Cmax is reached in approximately 2 hours and is 340 ng / ml. Repeated doses of the drug do not lead to its accumulation in the body. In vitro experiments have shown that 98.4% to 98.6% of the drug binds to plasma proteins. Metabolism and excretion1 / 2 is approximately 1.0 h. Approximately 10% of the drug is excreted by the kidneys, mainly in unchanged form. When taken at a dose of 600 mg, traces of the hydroxylated metabolite can be isolated.

Indications

-gastric ulcer; – chronic gastritis with increased acid-forming function of the stomach in the acute phase, erosive gastritis;- prevention of mucosal damage while taking NSAIDs; Can be used as part of combination therapy.

Contraindications

-individual intolerance to ribamipid or other components of the drug;— pregnancy— – lactation period;— under 18 years of age.

Side effects

From the digestive system: constipation, flatulence, diarrhea, nausea, vomiting, abdominal pain, impaired taste, heartburn. From the liver: signs of liver dysfunction, increased serum ALT and ACT. From the hematopoietic system: leukopenia, granulocytopenia. Other: violation of the menstrual cycle.

Interaction

When using rebamipide as part of traditional treatment regimens for patients with Helicobacter pylori infection, the effectiveness of eradication therapy significantly increases. Interactions with other drugs have not been studied.

How to take, course of use and dosage

Inside,1 tablet 3 times a day, washed down with a small amount of liquid. The course of treatment is 2-4 weeks, if necessary, it can be extended to 8 weeks. The drug does not have any special effects when taken for the first time or when it is canceled. If you miss taking one dose, you should take the next dose of the drug at the set time, do not take twice the dose of the drug.

Overdose

The symptoms of rebamipide overdose have not been described, and no cases of deliberate overdose have been reported to date. Nausea, vomiting, abdominal pain, diarrhea or constipation, and headache may occur. Treatment: No specific antidote is known. In case of overdose, the stomach should be washed and symptomatic therapy should be performed.

Special instructions

The safety of using rebamipide during pregnancy has not been proven. Do not use during pregnancy. Since rebamipid is excreted in breast milk, breast-feeding should be discontinued or artificial feeding of the child should be considered if it is necessary to prescribe rebamipid to the mother during lactation. Use in children contraindicated in children under 18 years of age. Use in elderly patientsthe first appointment of rebamipide to elderly patients due to the possibility of hypersensitivity to the drug. The effect of the drug on the speed of psychomotor reactions and/or the ability to drive vehicles or mechanisms has not been studied. In the case of taking the drug, you should be careful about driving a car and other activities that require increased concentration of attention.

Form of production

Tablets with a film-coated white or almost white color, round, biconvex.

Storage conditions

The drug should be stored out of the reach of children, dry, protected from light, at a temperature not exceeding 25°C.

Shelf

life is 2 years.

Active ingredient

Rebamipid

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

For adults as directed by your doctor

Indications

Gastric and duodenal ulcers, Gastritis, Heartburn